Alpine Immune Sciences
Remy Durand is a seasoned professional in the healthcare investment sector, currently serving as Principal at Alpine BioVentures since 2018, and as Chief Business Officer at Alpine Immune Sciences, Inc., where significant contributions include leading business development and corporate strategy during the company's acquisition by Vertex Pharmaceuticals. Prior experience includes a Vice President role at Frazier Healthcare Partners and as a Senior Associate at GE Ventures Healthcare, focusing on portfolio management and investment evaluation. Durand's earlier career encompassed consulting roles in the medical device field and internships with innovation-focused organizations, complemented by a strong academic background with a PhD in Bioengineering from Stanford University and a BSE in Biomedical Engineering from Case Western Reserve University.
This person is not in any offices
Alpine Immune Sciences
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), is a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases. With world-class research and development capabilities, a highly productive scientific platform, and a proven management team, Alpine is seeking to create first- orbest-in-class multifunctional immunotherapies via unique protein engineering technologies to improve patients’ lives. Alpine has entered into strategic collaborations with leading global biopharmaceutical companies and has a diverse pipeline of clinical and preclinical candidates in development.